2.35

0.42% -0.010

Palisade Bio Inc (PALI)

Overview News Price History Financials Discussions Forecast Stock Split

Palisade Bio Inc stock is traded at $2.35, with a volume of 4.25M. It is down -0.42% in the last 24 hours and up +11.37% over the past month. Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Previous Close:

$2.36

Open:

$2.35

24h Volume:

4.25M

Relative Volume:

0.47

Market Cap:

$350.63M

Revenue:

Net Income/Loss:

$-14.07M

P/E Ratio:

-0.168

EPS:

-13.99

Net Cash Flow:

$-12.56M

1W Performance:

+6.82%

1M Performance:

+11.37%

6M Performance:

+245.54%

1Y Performance:

+42.42%

1-Day Range:

$2.24

$2.37

1-Week Range:

$2.1021

$2.64

52-Week Range:

$0.53

$2.64

Palisade Bio Inc Stock (PALI) Company Profile

Name

Palisade Bio Inc

Sector

Healthcare (1130)

Industry

Biotechnology (631)

Phone

(858) 704-4900

Address

7750 EL CAMINO REAL, SUITE 5200, CARLSBAD

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

PALI's Discussions on Twitter

Compare PALI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PALI Palisade Bio Inc	2.35	352.12M	0	-14.07M	-12.56M	-13.99
VRTX Vertex Pharmaceuticals Inc	453.36	115.12B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	771.87	81.34B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	397.65	52.48B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	840.95	51.59B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	174.04	37.13B	447.02M	-1.18B	-906.14M	-6.1812

Palisade Bio Inc Stock (PALI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-29-25	Initiated	Piper Sandler	Overweight

Palisade Bio Inc Stock (PALI) Latest News

Dec 30, 2025

9,119,152 Common Stock of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com

Dec 30, 2025

Certain Stock Options of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com

Dec 30, 2025

Certain Warrants of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com

Dec 30, 2025

Palisade Bio receives patent approval in Japan for IBD drug PALI-2108 - Investing.com Nigeria

Dec 30, 2025

Palisade Bio Says Japan Grants Patent for Composition of PALI-2108 - marketscreener.com

Dec 30, 2025

Palisade Bio Secures Key Patent for PALI-2108, a Promising PDE4 Inhibitor for Ulcerative Colitis and Fibrostenotic Crohn’s Disease - Quiver Quantitative

Dec 30, 2025

Palisade Bio Announces Granting of Japanese Patent Covering - GlobeNewswire

Dec 30, 2025

Palisade Bio (NASDAQ:PALI) Upgraded at Piper Sandler - MarketBeat

Dec 30, 2025

Dec 29, 2025

Palisade Bio stock initiated with Buy rating at Clear Street on IBD drug potential - Investing.com

Dec 29, 2025

Palisade Bio Appoints New VP to Drive Further Growth - StocksToTrade

Dec 29, 2025

DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday - Benzinga

Dec 29, 2025

PALI’s Strategic Move: What’s Next? - timothysykes.com

Dec 29, 2025

Piper Sandler initiates Palisade Bio stock with Overweight rating on IBD drug By Investing.com - Investing.com Nigeria

Dec 29, 2025

Piper Sandler initiates Palisade Bio stock with Overweight rating on IBD drug - Investing.com Nigeria

Dec 29, 2025

Dec 28, 2025

Palisade Bio (PALI) soars 5% ahead of clinical trial results - MSN

Dec 28, 2025

Dec 26, 2025